The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 30 March 2026•Updated 1 April 2026•

1 min read

Medicus Pharma Reports 80% Response Rate in SkinJect Phase 2 Clinical Trials

Key Facts

1Medicus Pharma reported an 80% overall response rate (ORR) in Phase 2 data for SkinJect.

2 months ago

Version History

1 additional source confirmed this story

Version 12 months ago

What changed: Medicus Pharma provided additional guidance and clarification regarding the interpretation of its previously reported Phase 2 clinical data, specifically emphasizing drug-driven efficacy.

Medicus Pharma (MDCX) has announced the successful validation of its Phase 2 clinical trial data for SkinJect, reporting a significant overall response rate (ORR) of 80%. Following the initial report, the company issued formal guidance to clarify the interpretation of the Phase 2 topline dataset. This clarification emphasizes a specific focus on drug-driven efficacy in the treatment of non-melanoma skin cancer. Dr. Babar Rao, acting as a Key Opinion Leader (KOL), confirmed that these outcomes are clinically meaningful and support the drug's viability as a non-surgical alternative. The treatment could potentially allow a majority of patients to avoid immediate surgical intervention and its associated risks. Analysts view this detailed guidance as a move to strengthen investor confidence in the company's lead product and its future prospects in the biotech market.